IMPROVING EFFICIENCY IN ELASTOMERIC PUMP FILLING USING DIANA ONCO PLUS, A SEMI-AUTOMATED COMPOUNDING DEVICE

TCH-020

Purpose
To compare the time spent and the accuracy in the filling of elastomeric pumps (EPs) with fluorouracil by two different methods: DIANA ONCO-PLUS, a semi-automated compounding system (ICU Medical Europe), and the normal manual method used in the hospital’s Chemotherapy Unit (CU). The secondary endpoint was to assess user satisfaction with the two methods.

Materials and Methods
For 4 consecutive weeks, EPs were filled by trained nurses two days per week. The first day DIANA ONCO-PLUS was used and the second day the EPs were filled manually. To avoid bias, every week a different nurse filled the EPs using both methods. Filling time was measured by a different nurse using a conventional chronograph and the accuracy was evaluated by weight of EP (before and after filling). Nurses’ satisfaction was assessed by a questionnaire.

Results
The filling of sixty-five EPs was evaluated. The filling mean time was 4.25 min with the manual method and 3.84 min with DIANA ONCO-PLUS (p = 0.008). If purge is considered, the mean time was 6.65 min and 5.52 min respectively (p < 0.001). The mean relative error in the filling was 0.735% in manual method and 0.314% in DIANA method (p = 0.006) without any clinical relevance. There was no user-related variability. Nurses were very satisfied using DIANA for filling EP. They considered DIANA more comfortable and safe.

Conclusions
DIANA ONCO-PLUS is a more efficient and accurate method to fill EPs than the manual method. The differences found were user-independent.

Acknowledgements
The authors thank the Pharmacy Department of HUP La Fe, Nagore Castro, Loreto Gómez (Hospira PFH SL) and Roberto Zambrano (ICU Medical) for their collaboration in this study.

No conflict of interest.

INTRADIALYTIC CALCIPHYLAXIS IN RENAL PATIENTS. DEVELOPMENT OF AN INJECTABLE SOLUTION OF 25% SODIUM THIOSULFATE FOR TREATMENT

TCH-022

Purpose
To describe the method of preparation and checking of an injectable solution of 25% sodium thiosulfate for the treatment of intradialytic calciphylaxis in renal patients.

Materials and Methods
Sodium thiosulfate is an antioxidant, vasodilator and calcium chelator. The preparation process for the solution of 25% sodium thiosulfate is: Ingredients: Sodium thiosulfate pentahydrate: 25 g, water for injection (WFI): qs 100 ml. Preparation: Weigh the amount of sodium thiosulfate in a sterile beaker. Then, working in a horizontal laminar flow hood, boil WFI to eliminate CO₂. Dissolve the thiosulfate in about 80 ml of boiled water. Check that the pH of the solution is between 6 and 9, if it is not, adjust with HCl or NaOH. Flush into a 100 ml volumetric flask and make up to volume. Filter with a double 0.22 micron filter. Finally pack with 50 ml syringe into a sterile glass bottle and label.

Results
The result is a solution of 100 ml of 25% sodium thiosulfate, transparent, sterile and stable for 30 days in refrigerator. For QC a visual particulate sterility check is performed by sowing in aerobic and anaerobic cultures and a bubble point test to verify the integrity of the vials.

Conclusions
Proper preparation and checking of the 25% solution of sodium thiosulfate has guaranteed its parenteral administration is safe. The treatment is effective and well tolerated, helping patients and improving their quality of life.

No conflict of interest.

INCORPORATION OF IL28B POLYMORPHISM ASSESSMENT INTO THE SERVICES PORTFOLIO OF THE PHARMACY DEPARTMENT AND RESULTS OBTAINED

TCH-021

Purpose
To describe the implementation of the determination of the IL-28B polymorphism, rs12979860, and the results obtained, in order to personalise the treatment in HCV mono-infected patients in a tertiary hospital.

Materials and Methods
We designed a standard form for HCV patients starting treatment with protease inhibitors. It includes several items that require clinical evaluation: viral load, HCV genotype, FibroScan and/or liver biopsy, response to previous treatment and polymorphism of the IL-28B genotype. Homozygous CC is the favourable genotype, predicting a good response. CT and TT genotypes are considered unfavourable.

The test was conducted in the pharmacogenetics area of the pharmacy department. To calculate the response time, we considered how long it takes to get the different responses.

The results were added to the hospital’s electronic medical records programme for easy reference online.

Results
A total of 26 genotypes was determined, of which 11 (42%) were requested by the department of infectious diseases (56% co-infected), 10 (38%) by the hepatology department and 5 (18%) by an external department. Results 15 (58%) were CT, 8 (31%) CC and 3 (11%) TT. 100% of patients had a score of FibroScan > 9.5 kPascal. The response for the tests was on average 3 to 7 days, with the limiting factor the sequencer availability.

Conclusions
IL28B determination has been added to the hospital’s services portfolio as a clinical assessment tool for the treatment of hepatitis C, with a response time of 3–7 days.

No conflict of interest.